Eradication of pathogenic β-catenin by Skp1/Cullin/F box ubiquitination machinery

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  2003-10-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/pnas.2133261100PMID 14563921PMCID PMC240686
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase.

  2003cited by this paper
• Structure of a -TrCP1-Skp1--Catenin Complex

  2003cited by this paper
• Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase.

  2003cited by this paper
• Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells.

  2002cited by this paper
• The -Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells

  2002cited by this paper
• Oncogenic β-Catenin Is Required for Bone Morphogenetic Protein 4 Expression in Human Cancer Cells

  2002cited by this paper
• Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation.

  2002cited by this paper
• The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells.

  2002cited by this paper
• Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation

  2002cited by this paper
• Proof-of-principle: oncogenic beta-catenin is a valid molecular target for the development of pharmacological inhibitors.

  2002cited by this paper
• Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation

  2001cited by this paper
• Linking colorectal cancer to Wnt signaling.

  2000cited by this paper
• Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins.

  2000cited by this paper
• The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression.

  2000cited by this paper
• An F‐box protein, FWD1, mediates ubiquitin‐dependent proteolysis of β‐catenin

  1999cited by this paper
• Essential role for oncogenic Ras in tumour maintenance

  1999cited by this paper
• Using Antibodies: A Laboratory Manual

  1999cited by this paper
• Transient excess of MYC activity can elicit genomic instability and tumorigenesis.

  1999cited by this paper
• Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3beta and beta-catenin and promotes GSK-3beta-dependent phosphorylation of beta-catenin.

  1998cited by this paper
• beta-TrCP is a negative regulator of Wnt/beta-catenin signaling pathway and dorsal axis formation in Xenopus embryos.

  1998cited by this paper
• Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta.

  1998cited by this paper
• The role of protein stability in the cell cycle and cancer.

  1998cited by this paper
• Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK‐3β and β‐catenin and promotes GSK‐3β‐dependent phosphorylation of β‐catenin

  1998cited by this paper
• Identification of c-MYC as a target of the APC pathway.

  1998cited by this paper
• beta-catenin is a target for the ubiquitin-proteasome pathway.

  1997cited by this paper
• β‐catenin is a target for the ubiquitin–proteasome pathway

  1997cited by this paper
• Yeast surface display for screening combinatorial polypeptide libraries

  1997cited by this paper
• Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC

  1997cited by this paper
• Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma

  1997cited by this paper
• The adenomatous polyposis coli (APC) tumor suppressor.

  1997cited by this paper
• de la Chapelle, A.

  1997cited by this paper
• Amyloid β-Protein and the Genetics of Alzheimer's Disease*

  1996cited by this paper
• Functional interaction of β-catenin with the transcription factor LEF-1

  1996cited by this paper
• Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly.

  1996cited by this paper
• Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly

  1996cited by this paper
• SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box.

  1996cited by this paper
• Functional interaction of beta-catenin with the transcription factor LEF-1.

  1996cited by this paper
• Apoptosis and APC in colorectal tumorigenesis.

  1996cited by this paper
• Cadherin‐catenin complex: Protein interactions and their implications for cadherin function

  1996cited by this paper
• Defective protein folding as a basis of human disease.

  1995cited by this paper
• The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin.

  1995cited by this paper
• Redirecting the specificity of ubiquitination by modifying ubiquitin-conjugating enzymes.

  1995cited by this paper
• Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein.

  1995cited by this paper
• The APC Protein and E-cadherin Form Similar but Independent Complexes with α-Catenin, β-Catenin, and Plakoglobin (*)

  1995cited by this paper
• p21 is necessary for the p53-mediated G1 arrest in human cancer cells.

  1995cited by this paper
• Altered growth of human colon cancer cell lines disrupted at activated Ki-ras.

  1993cited by this paper
• Hypermutability and mismatch repair deficiency in RER+ tumor cells.

  1993cited by this paper
• Association of the APC gene product with beta-catenin.

  1993cited by this paper
• Association of the APC tumor suppressor protein with catenins.

  1993cited by this paper
• The ubiquitin system for protein degradation.

  1992cited by this paper
• A novel genetic system to detect protein–protein interactions

  1989cited by this paper

• Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics

  2025cites this paper
• Development of a targeted BioPROTAC degrader selective for misfolded SOD1

  2025cites this paper
• DARPins as a novel tool to detect and degrade p73

  2024cites this paper
• Programmable protein degraders enable selective knockdown of pathogenic β-catenin subpopulations in vitro and in vivo

  2024cites this paper
• Neddylation of HER2 Inhibits its Protein Degradation and promotes Breast Cancer Progression

  2023cites this paper
• Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)

  2023cites this paper
• Targeted protein degradation in mammalian cells: A promising avenue toward future

  2022cites this paper
• Design of Peptide-Based Protein Degraders via Contrastive Deep Learning

  2022cites this paper
• Targeting UBE2C for degradation by bioPROTACs based on bacterial E3 ligase

  2022cites this paper
• Ubiquitin-specific protease 53 promotes osteogenic differentiation of human bone marrow-derived mesenchymal stem cells

  2021cites this paper
• bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA)

  2020cites this paper
• Targeted Intracellular Degradation of SARS-CoV-2 RBD via Computationally-Optimized Peptide Fusions

  2020cites this paper
• SKP1 promotes YAP-mediated colorectal cancer stemness via suppressing RASSF1

  2020cites this paper
• Targeted intracellular degradation of SARS-CoV-2 via computationally optimized peptide fusions

  2020cites this paper
• bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA)

  2019cites this paper
• The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.

  2019cites this paper
• Blood vessel epicardial substance (BVES) reduces LRP6 receptor and cytoplasmic -catenin levels to modulate Wnt signaling and intestinal homeostasis.

  2019cites this paper
• Targeted Intracellular Delivery of Antibodies: The State of the Art

  2018cites this paper
• Molecular tool development for conditional protein degradation in the model bacterium Escherichia coli

  2018cites this paper
• Wnt Signaling as a Therapeutic Target in Cancer and Metastasis

  2017cites this paper
• CSF-Based Analysis for Identification of Potential Serum Biomarkers of Neural Tube Defects

  2017cites this paper
• Small-Molecule Modulation of Protein Homeostasis.

  2017cites this paper
• WNT signaling in glioblastoma and therapeutic opportunities

  2016cites this paper
• Protein engineering strategies with potential applications for altering clinically relevant cellular pathways at the protein level

  2016cites this paper
• Targeting cullin-RING ligases for cancer treatment: rationales, advances and therapeutic implications

  2015influential citation
• Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

  2015cites this paper
• Chimeric ubiquitin ligases inhibit non-small cell lung cancer via negative modulation of EGFR signaling.

  2015cites this paper
• Atypical ubiquitin E3 ligase complex Skp1-Pam-Fbxo45 controls the core epithelial-to-mesenchymal transition-inducing transcription factors

  2014cites this paper
• Understanding kinetochore dependency pathways using vertebrate conditional knockout cell lines and quantitative proteomics

  2014cites this paper
• Generic tools for conditionally altering protein abundance and phenotypes on demand

  2014cites this paper
• Engineered ubiquitin ligase PTB-U-box targets insulin/insulin-like growth factor receptor for degradation and coordinately inhibits cancer malignancy

  2014cites this paper
• Engineering New Protein–Protein Interactions on the β‐Propeller Fold by Yeast Cell Surface Display

  2013cites this paper
• Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases

  2013cites this paper
• Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth In Vitro and In Vivo

  2013cites this paper
• 7 Putting genetics into optogenetics: knocking out proteins with light

  2013cites this paper
• Signaling Pathways in Cancer Pathogenesis and Therapy

  2012cites this paper
• Wnt Signaling in Cancer Pathogenesis and Therapeutics

  2012cites this paper
• The ends and means of artificially induced targeted protein degradation

  2012cites this paper
• Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

  2011cites this paper
• Antitumor effect of F-PBF(beta-TrCP)-induced targeted PTTG1 degradation in HeLa cells.

  2009cites this paper
• Oxygen-independent degradation of HIF-α via bioengineered VHL tumour suppressor complex

  2009cites this paper
• RVB1/RVB2: running rings around molecular biology.

  2009cites this paper
• Targeting proteins for degradation.

  2009cites this paper
• Targeting Deubiquitinating Enzymes

  2009cites this paper
• The role of the F-Box protein Frp1 in pathogenicity of fusarium oxysporum

  2009cites this paper
• Prognostic and therapeutic implications of Apc mutations in colorectal cancer.

  2008cites this paper
• APC is essential for targeting phosphorylated beta-catenin to the SCFbeta-TrCP ubiquitin ligase.

  2008cites this paper
• An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics.

  2008cites this paper
• Targeting the most upstream site of Wnt signaling pathway provides a strategic advantage for therapy in colorectal cancer.

  2008cites this paper
• Wnt signaling and human diseases: what are the therapeutic implications?

  2007cites this paper
• Targeting the Wnt signaling pathway to treat Barrett’s esophagus

  2007cites this paper
• Quantitative Phosphoproteome Profiling of Wnt3a-mediated Signaling Network

  2007cites this paper
• Degradation of HER2 by Cbl-based chimeric ubiquitin ligases.

  2007influential citation
• Wnt signaling in stem cells and lung cancer.

  2006cites this paper
• Conditional control of protein function

  2006cites this paper
• Method for targeting protein destruction by using a ubiquitin-independent, proteasome-mediated degradation pathway.

  2005cites this paper
• Wnt/beta-catenin-pathway as a molecular target for future anti-cancer therapeutics.

  2005cites this paper
• Wnt/β‐catenin‐pathway as a molecular target for future anti‐cancer therapeutics

  2005cites this paper
• Ectopic targeting of substrates to the ubiquitin pathway.

  2005cites this paper
• Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation.

  2005cites this paper
• Targeted protein degradation.

  2005cites this paper
• Transient in utero knockout (TIUKO) of C-MYC affects late lung and intestinal development in the mouse

  2004cites this paper
• Wnt/beta-catenin signaling pathway as a novel cancer drug target.

  2004cites this paper
• Targeted degradation of beta-catenin by chimeric F-box fusion proteins.

  2004cites this paper
• Targeted degradation of β-catenin by chimeric F-box fusion proteins

  2004cites this paper
• ReviewConditional Control of Protein Function

  year unknowncites this paper